Pharming Group (NASDAQ:PHAR) Shares Gap Up to $8.49

Pharming Group (NASDAQ:PHAR) shares gapped up before the market opened on Thursday . The stock had previously closed at $8.49, but opened at $8.77. Pharming Group shares last traded at $8.77, with a volume of 103 shares trading hands.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research note on Friday, May 31st.

Pharming Group Stock Down 6.0 %

The business’s fifty day simple moving average is $8.53 and its 200-day simple moving average is $10.20.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.20). The company had revenue of $55.59 million during the quarter, compared to the consensus estimate of $68.43 million. Pharming Group had a negative net margin of 4.01% and a negative return on equity of 4.61%. On average, equities research analysts predict that Pharming Group will post -0.03 earnings per share for the current year.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,435 shares of the company’s stock after buying an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.